US patent secured for PromarkerEndo
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Proteomics International Laboratories Ltd. has secured a US patent for its PromarkerEndo diagnostic test for endometriosis, as reported by the United States Patent and Trademark Office on page one. This patent represents a significant milestone for the company, enhancing its intellectual property portfolio and supporting future commercialization efforts in a major healthcare market on page one.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Proteomics International Laboratories Ltd. on 6ix
Story so far
Earlier from Proteomics International Laboratories
- Proteomics Strategic Plan
- Restructure, Executive Appointment and Board Update
- Appendix 4D and Interim Financial Report
- Quarterly Activities/Appendix 4C Cash Flow Report
- Canadian patent secured for PromarkerEso test for EAC
Later from Proteomics International Laboratories
- Proteomics signs national distribution deal with Healius
- Australian patent for PromarkerEndo
- Appendix 4E and Annual Report
- PromarkerD and PromarkerEso Commercial Rollout Update
- PromarkerEndo Validation and Refinement Complete
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories